Yahoo Finance
Novo Nordisk A/S (NYSE:NVO) looks to open a new growth avenue for its blockbuster obesity drug Wegovy by targeting the pediatric market.
In the late-stage STEP Young trial, semaglutide (the active ingredient in Wegovy) produced strong results in young children.
In the trial, 40.4% of children treated with semaglutide were no longer classified as having obesity after 68 weeks, assuming adherence to treatment, compared with none receiving placebo.
The result could expand the addressable market for Wegovy.
But investors still need to see whether Novo can convert a successful clinical trial into a meaningful commercial opportunity.
The STEP Young trial met its primary endpoint.
Semaglutide demonstrated a superior reduction in body mass index at week 68 compared with placebo.
In addition to taking semaglutide once weekly, all trial participants also received lifestyle modifications.
These included a reduced-calorie diet and increased physical activity.
That aside, the magnitude of the result gives Novo a pathway into a potentially large new market.
Although GLP-1 weight-loss drugs are not currently approved for children under 12 in the U.S., a recent study offers a glimpse into the demand.
The study, published September 4 in the Pediatrics journal, revealed that GLP-1 weight-loss drug prescribing among children ages 8 to 11 with obesity and without diabetes increased roughly 310-fold from 2019 to 2026.
| Product | Price | Change |
|---|---|---|
| Brent Crude | $102.14/bbl | +0.34% |
| WTI Crude | $96.90/bbl | +0.21% |
| EN590 Diesel | $846/MT | +0.18% |
| Jet Fuel A-1 | $1090/MT | +0.55% |
| Mazut M100 | $450/MT | -0.15% |
| Bitumen 60/70 | $470/MT | +0.08% |
| Sulphur Gran 99.5% | $470/MT | -0.44% |
| Urea 46% Gran | $650/MT | +1.12% |
| NPK 16-16-16 | $460/MT | -0.28% |
| Nat Gas TTF | $15.42/MMBtu | +0.92% |
Comments
Post a Comment